Literature DB >> 16333707

Staging and follow-up of gastrointestinal tumors with PET/CT.

S J Rosenbaum1, H Stergar, G Antoch, P Veit, A Bockisch, H Kühl.   

Abstract

Positron emission tomography (PET) is a functional imaging modality that has been documented to be useful in patient care. Oncologic PET imaging is used for a wide variety of neoplasms, mainly for staging and follow-up, differentiation of equivocal morphologic findings, therapy stratification, and monitoring. Because PET imaging is based on the physiologically mediated distribution of the administered tracer but not on anatomic information, the addition of computed tomography (CT) to PET may improve the interpretation of PET. Combined PET and CT offers several potential advantages over PET alone that may influence the clinical routine. PET/CT was introduced into clinical use only 3 years ago and has found widespread application within only 1 to 2 years. This article summarizes preliminary data of clinical applications for PET/CT in gastrointestinal tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16333707     DOI: 10.1007/s00261-005-0031-3

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  23 in total

1.  Successful diagnosis of gallbladder carcinoma coexisting with adenomyomatosis by 18F-FDG-PET--report of a case.

Authors:  Keiichi Suzuki; Susumu Watada; Mitsui Yoko; Tadaki Nakahara; Yusuke Kumamoto
Journal:  J Gastrointest Cancer       Date:  2011-12

Review 2.  Updates on Management of Gastric Cancer.

Authors:  Fabian M Johnston; Michael Beckman
Journal:  Curr Oncol Rep       Date:  2019-06-24       Impact factor: 5.075

3.  Clinical Value of a One-Stop-Shop Low-Dose Lung Screening Combined with (18)F-FDG PET/CT for the Detection of Metastatic Lung Nodules from Colorectal Cancer.

Authors:  Yeon-Hee Han; Seok Tae Lim; Hwan-Jeong Jeong; Myung-Hee Sohn
Journal:  Nucl Med Mol Imaging       Date:  2015-12-17

4.  Perioperative chemotherapy for gastroesophageal cancer in British Columbia: a multicentre experience.

Authors:  R D Peixoto; W Y Cheung; H J Lim
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

5.  [Nuclear medical diagnostics for liver tumors].

Authors:  A K Buck; J C Stollfuss; A Stahl; A J Beer; G Meisetschläger; M Schwaiger
Journal:  Internist (Berl)       Date:  2007-01       Impact factor: 0.743

6.  Impact of PET-CT on primary staging and response control on multimodal treatment of esophageal cancer.

Authors:  Kirsten Thurau; Daniel Palmes; Christiane Franzius; Evgeny Minin; Norbert Senninger; Kai Uwe Juergens; Matthias Bruewer
Journal:  World J Surg       Date:  2011-03       Impact factor: 3.352

7.  Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer: the maximal SUV of the stomach is a prognostic factor.

Authors:  Jun Chul Park; Jae-Hoon Lee; Kungseok Cheoi; Hyunsoo Chung; Mi Jin Yun; Hyuk Lee; Sung Kwan Shin; Sang Kil Lee; Yong Chan Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-04-18       Impact factor: 9.236

8.  The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab.

Authors:  Francesca Di Fabio; Carmine Pinto; Fabiola L Rojas Llimpe; Stefano Fanti; Paolo Castellucci; Ciro Longobardi; Vita Mutri; Chiara Funaioli; Francesca Sperandi; Stefania Giaquinta; Andrea A Martoni
Journal:  Gastric Cancer       Date:  2007-12-25       Impact factor: 7.370

9.  Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer.

Authors:  Hisao Wakabayashi; Yoshihiro Nishiyama; Tsuyoshi Otani; Takanori Sano; Shinichi Yachida; Keiichi Okano; Kunihiko Izuishi; Yasuyuki Suzuki
Journal:  World J Gastroenterol       Date:  2008-01-07       Impact factor: 5.742

Review 10.  PET/CT in oncology: for which tumours is it the reference standard?

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.